List of Excipients in Branded Drug EYSUVIS

Eysuvis Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Eysuvis is a 0.25% loteprednol etabonate ophthalmic suspension approved for the short-term treatment of dry-eye disease signs and symptoms. Its excipient system is built around suspension stability, ocular comfort, pH control, wetting, lubrication, and dose uniformity rather than antimicrobial preservation. The formulation creates commercial opportunities in preservative-free delivery, single-dose packaging, chronic dry-eye products, generic substitution barriers, and differentiated corticosteroid combinations.

What is Eysuvis and how is it formulated?

Eysuvis contains loteprednol etabonate, a corticosteroid, at a concentration of 0.25%. It is supplied as a topical ophthalmic suspension for use four times daily for up to two weeks. Kala Pharmaceuticals developed the product using its mucus-penetrating particle technology, which is intended to improve distribution across the ocular surface and support drug delivery in the presence of tear-film and mucin barriers.[1,2]

Eysuvis composition

The FDA-approved label identifies the following inactive ingredients:

Excipient	Primary formulation role
Glycerin	Tonicity adjustment and ocular comfort
Edetate disodium	Chelation of trace metals and support for chemical stability
Boric acid	Buffering and tonicity contribution
Sodium borate decahydrate	pH buffering and ionic-strength control
Polysorbate 80	Wetting and particle-dispersion aid
Povidone	Lubrication, viscosity modification, and surface retention
Purified water	Vehicle
Hydrochloric acid and/or sodium hydroxide	pH adjustment, where required

The labeled pH range is approximately 5.5 to 6.5, with osmolality targeted to a range compatible with ocular administration.[1]

Eysuvis does not use benzalkonium chloride as a listed inactive ingredient. The absence of BAK is commercially relevant because repeated exposure to BAK can aggravate ocular-surface irritation and epithelial damage in some patients, particularly those with chronic dry-eye disease or frequent topical-drug use.[3]

How does the Eysuvis excipient strategy support performance?

The formulation addresses the principal technical problems associated with ophthalmic suspensions: particle sedimentation, redispersion, dose variability, ocular irritation, and limited residence time.

Why are glycerin, borate, and povidone important?

Glycerin helps bring the formulation toward ocular-compatible tonicity and can reduce the stinging associated with hypotonic or hypertonic drops. The boric acid and sodium borate pair provides buffering and contributes to the ionic environment of the suspension.

Povidone is a water-soluble polymer used widely in ophthalmic products as a lubricant and viscosity modifier. In Eysuvis, it can support comfort and increase the time that suspended particles remain in contact with the ocular surface. Its contribution is likely functional rather than merely cosmetic because low-viscosity ophthalmic suspensions must balance residence time with visual blurring and dropability.

What is the role of polysorbate 80?

Polysorbate 80 is a nonionic surfactant. It can improve wetting of hydrophobic loteprednol etabonate particles, reduce particle agglomeration, and promote uniform redispersion after shaking.

For a corticosteroid suspension, this function has direct commercial importance. If particles agglomerate or settle into a compact cake, the first and last doses may contain different drug concentrations. A surfactant-supported suspension can reduce that risk, although the finished product still requires shaking before use.

Why is edetate disodium included?

Edetate disodium binds trace metal ions that can catalyze oxidation or other degradation reactions. Its use can improve chemical stability and protect the formulation during storage. In ophthalmic products, chelation can also affect preservative systems, although Eysuvis does not list a conventional antimicrobial preservative.

What commercial advantages come from a preservative-free Eysuvis formulation?

The absence of BAK gives Eysuvis a positioning advantage in patients with ocular-surface sensitivity, contact-lens-related irritation, meibomian-gland dysfunction, and repeated-use dry-eye treatment. The advantage is strongest against preserved steroid drops and preserved artificial tears.

Eysuvis is prescribed for short-term anti-inflammatory treatment rather than indefinite maintenance therapy. Its commercial value therefore depends on:

1. Rapid treatment of dry-eye flares.
2. Use before or alongside long-term immunomodulatory therapy.
3. Better tolerability than preserved corticosteroid products.
4. Product differentiation against generic loteprednol suspensions.
5. Physician preference for a formulation designed specifically for dry-eye disease.

A preservative-free profile does not automatically establish clinical superiority. The commercial claim must remain tied to ocular-surface tolerability, patient adherence, and the product’s approved indication.

What formulation patents and intellectual-property barriers protect Eysuvis?

The principal intellectual-property value is likely concentrated in the formulation and particle-engineering platform rather than in the loteprednol etabonate molecule itself. Loteprednol etabonate is an established corticosteroid, so composition-of-matter exclusivity for the active ingredient does not provide the primary barrier for Eysuvis.

Which technical features can create patent protection?

Potentially protectable features include:

• Particle-size distribution.
• Mucus-penetrating surface characteristics.
• Polymer or surfactant treatment of drug particles.
• Suspension stability and redispersion.
• Ophthalmic delivery of low-dose loteprednol etabonate.
• Use in dry-eye disease.
• Manufacturing processes for particle preparation.
• Packaging systems that preserve dose uniformity.
• Specific excipient ratios and concentration ranges.

The FDA approved Eysuvis under NDA 212660 in October 2020.[1] The product’s regulatory exclusivity was separate from any patent protection. For a new drug supported by clinical investigations, FDA 3-year exclusivity would ordinarily protect the approved clinical-use change from certain competing approvals through October 2023, assuming the exclusivity applied and was not modified by FDA records.[4]

What is the Orange Book status of Eysuvis?

Eysuvis is listed in the FDA Orange Book as a prescription drug product approved under NDA 212660. The Orange Book remains the controlling source for current patent listings, patent-use codes, and regulatory exclusivity status.[5]

An ANDA applicant challenging listed patents could submit a Paragraph IV certification. A generic applicant that provides a Paragraph IV notice may trigger patent litigation under the Hatch-Waxman framework. The resulting 30-month stay, settlement terms, and possible first-filer exclusivity would determine the practical generic-launch date.[6]

The commercial risk is likely greater from formulation and method-of-use patents than from the excipient names themselves. Glycerin, borate, povidone, polysorbate 80, and edetate disodium are established pharmaceutical excipients. Patent protection would need to arise from their defined combination, concentration ranges, performance characteristics, or use with a particular loteprednol particle system.

How strong is the Eysuvis patent estate?

The estate can be considered moderately defensible if it covers a narrow, difficult-to-design-around particle and suspension architecture. It is weaker if protection depends only on using known excipients with loteprednol etabonate.

Strength factors

Factor	Effect on patent strength
Proprietary particle engineering	Stronger barrier if measurable in the finished product
Defined particle-size distribution	Useful if generic products cannot avoid the claimed range without losing performance
Specific excipient ratios	Moderate protection; competitors may alter concentrations
Method-of-use claims for dry-eye disease	Can delay substitution if the generic label carries the same indication
Conventional excipients	Weak protection when claimed broadly
Manufacturing process claims	Stronger if process conditions determine critical particle attributes
Suspension performance data	Supports enablement and infringement analysis
Broad loteprednol claims	Vulnerable if the active ingredient and prior formulations are well established

The strongest commercial position would combine product claims, process claims, and method-of-use claims. A formulation-only estate is more exposed to an alternative generic suspension using different surfactants, polymers, or particle-processing conditions.

What generic entry risks exist for Eysuvis?

Eysuvis is a small-molecule product, so biosimilar competition is not relevant. Competition would come through an ANDA for a therapeutically equivalent ophthalmic suspension.

Generic substitution scenarios

Scenario	Commercial effect
Same active ingredient, strength, dosage form, and route	Direct substitution risk
Different excipient system with equivalent performance	Potentially meaningful erosion
Preserved generic suspension	Price competition but possible tolerability differentiation
Generic with a narrower label	Slower substitution if pharmacy substitution is limited
Paragraph IV challenge	Earlier litigation and potential launch before all listed patents expire
Authorized generic	Lower-cost product under the brand owner’s control
Alternative loteprednol formulation	Indirect pressure on price and prescribing

FDA approval of a generic suspension requires pharmaceutical equivalence and bioequivalence under the applicable ANDA standards. The generic does not need to copy every excipient, but it must meet the relevant quality and performance requirements.[7]

A generic applicant may attempt a design-around by changing the surfactant, polymer, buffer, or particle-processing method. That strategy can avoid narrow formulation claims, but it creates development risk because ophthalmic suspensions are sensitive to particle size, viscosity, redispersion, sterility, preservative performance, and container compatibility.

What commercial opportunities exist for Eysuvis excipients?

1. Preservative-free multidose delivery

The existing formulation supports a strong commercial case for preservative-free multidose packaging. The opportunity is to preserve sterility without adding BAK or another conventional antimicrobial preservative. This could involve specialized multidose valve systems, sterile barrier packaging, or unit-dose formats.

The packaging system becomes part of the commercial proposition. A preservative-free multidose product can command a premium if it reduces irritation and improves use in patients requiring repeated topical treatment.

2. Unit-dose Eysuvis

Unit-dose packaging could target patients with severe ocular-surface disease, post-procedure inflammation, or sensitivity to multidose containers. The disadvantages are higher packaging cost, greater material use, and lower convenience for a four-times-daily regimen.

A unit-dose presentation could also support hospital, ambulatory-surgery, and specialty-pharmacy channels where sterility assurance and controlled dispensing have higher value.

3. Lower-viscosity and comfort-optimized versions

Povidone and glycerin provide a platform for investigating comfort, drop sensation, and residence time. A reformulation could seek to reduce transient blur, improve drop spread, or reduce the need for shaking. Any change would require new stability, dose-uniformity, container-closure, and clinical or regulatory support depending on the scope of the modification.

4. Longer-duration dry-eye treatment

The current indication is short term. A formulation with improved ocular retention or controlled release could support less frequent dosing or a longer treatment course. This is a larger opportunity but also carries greater safety risk because chronic topical corticosteroid exposure can raise intraocular pressure and contribute to cataract formation or infection.

5. Combination products

The excipient platform could support combinations with agents used in dry-eye disease or ocular inflammation. Potential targets include anti-infective agents, immunomodulators, antihistamines, or other anti-inflammatory drugs. Combination development would face compatibility, particle-size, dose-ratio, and regulatory-combination requirements.

6. Manufacturing and contract-development licensing

Companies with expertise in ophthalmic suspensions, sterile fill-finish, particle engineering, or preservative-free packaging could license platform know-how. The most valuable assets would be:

• Reproducible loteprednol particle production.
• Stable suspension manufacture at commercial scale.
• Low-shear filling that preserves particle distribution.
• Container systems that reduce settling and dose variability.
• Analytical methods for particle size, morphology, redispersion, and delivered-dose uniformity.

How does Eysuvis compare with other loteprednol products?

Product category	Typical formulation position	Excipient opportunity
Eysuvis 0.25% suspension	Short-term dry-eye anti-inflammatory treatment	Preservative-free comfort and mucus-penetrating delivery
Lotemax 0.5% suspension or gel	Broader corticosteroid indications	Strength, dosage form, and formulation differentiation
Generic loteprednol suspension	Lower-cost substitution	Alternative excipient system and price pressure
Loteprednol gel	Higher residence time and altered sensory profile	Viscosity and dosing-frequency competition
Fluorometholone or prednisolone products	Alternative ophthalmic corticosteroids	Cost, potency, safety, and tolerability comparison

Eysuvis has a lower loteprednol concentration than many older loteprednol products and is positioned specifically around dry-eye disease. Its excipient strategy is therefore part of the product identity, not an incidental formulation choice.

What FDA regulatory issues affect excipient-based line extensions?

FDA review would focus on product quality, sterility, stability, delivered-dose uniformity, particle-size distribution, redispersion, container closure, and ocular tolerability. A line extension may qualify for a supplemental NDA, a new NDA, or another regulatory pathway depending on the active ingredient, formulation changes, and proposed labeling.

A change in excipient concentration can alter:

• Drug-particle wetting.
• Sedimentation rate.
• Redispersion time.
• Drop size.
• Ocular residence time.
• Osmolality and pH.
• Preservative or sterility control.
• Container compatibility.

For Eysuvis, the commercial value of an excipient change is therefore inseparable from manufacturing validation and clinical usability. A technically simpler formulation may still fail if it produces inconsistent dosing or worsens patient comfort.

What litigation and settlement risks affect generic entry?

The principal litigation pathway is a Paragraph IV patent challenge under the Hatch-Waxman Act. A first ANDA filer may seek 180-day exclusivity if it meets statutory requirements. A settlement could establish a licensed generic-entry date, an authorized-generic arrangement, or restrictions on the challenged product’s label.

No biosimilar litigation pathway applies because loteprednol etabonate is a chemically synthesized small molecule. Competition will instead depend on Orange Book listings, ANDA filings, patent validity, infringement findings, and settlement terms.[5,6]

Key Takeaways

• Eysuvis uses glycerin, borate salts, povidone, polysorbate 80, edetate disodium, and water to support comfort, buffering, wetting, stability, and suspension performance.
• The formulation is preservative-free with respect to BAK, creating a positioning advantage for sensitive ocular surfaces.
• The most defensible intellectual property is likely tied to particle engineering, suspension performance, manufacturing, and use in dry-eye disease.
• Generic risk comes from ANDA applicants using alternative excipient systems and particle-processing methods.
• Biosimilar risk is irrelevant because Eysuvis contains a small-molecule active ingredient.
• The strongest commercial opportunities are preservative-free multidose packaging, unit-dose delivery, longer-duration formulations, combination products, and manufacturing-platform licensing.
• Eysuvis’ commercial differentiation depends on the interaction between excipients, particle technology, packaging, clinical tolerability, and dose uniformity.

FAQs

Can Eysuvis be reformulated without polysorbate 80?

Potentially, but removing polysorbate 80 could change wetting, aggregation, sedimentation, and redispersion. A replacement surfactant or polymer system would require comparative quality and stability development.

Is Eysuvis an artificial tear product?

No. Eysuvis is a corticosteroid ophthalmic suspension containing loteprednol etabonate. Its glycerin and povidone components may support comfort, but the product is intended for short-term treatment of dry-eye disease signs and symptoms, not routine tear replacement.

Could a generic Eysuvis use different excipients?

Yes. An ANDA product generally does not need to duplicate every inactive ingredient, provided it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and performance.

Does preservative-free status make Eysuvis suitable for chronic use?

No. The absence of BAK can support ocular-surface tolerability, but corticosteroid safety limits still apply. The approved regimen is short term, and extended use requires appropriate ophthalmic monitoring.

What is the most valuable excipient-related licensing asset around Eysuvis?

The highest-value asset is likely a validated combination of particle engineering, suspension processing, preservative-free sterile packaging, and analytical controls that produces consistent ocular delivery. Individual commodity excipients generally have limited standalone licensing value.

References

1. U.S. Food and Drug Administration. (2020). Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% prescribing information. Kala Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2020). Clinical review: Eysuvis NDA 212660. Center for Drug Evaluation and Research.

3. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.

4. U.S. Food and Drug Administration. (2023). New drug product exclusivity. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications. U.S. Department of Health and Human Services.

7. U.S. Food and Drug Administration. (2024). Bioequivalence studies for formulation changes and ophthalmic drug products. U.S. Department of Health and Human Services.